Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides

Bioconjugate Chemistry

Volumn 26, Issue 8, 2015, Pages 1713-1723

  Shinchi, Hiroyuki ^a,b   Crain, Brian ^a   Yao, Shiyin ^a   Chan, Michael ^a   Zhang, Shannon S ^a   Ahmadiiveli, Alast ^a   Suda, Yasuo ^b   Hayashi, Tomoko ^a   Cottam, Howard B ^a   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; IMMUNE SYSTEM; MOLECULES; POLYSACCHARIDES; SOLUTIONS; VACCINES;

ANTI-CANCER THERAPIES; ANTIVIRAL THERAPY; IMMUNOSTIMULATORY ACTIVITIES; INNATE IMMUNE SYSTEMS; LOW MOLECULAR WEIGHT; PATHOGEN-ASSOCIATED MOLECULAR PATTERNS; SIDE EFFECT; SMALL MOLECULES; TOLL-LIKE RECEPTORS; WATER SOLUBILITIES;

LIGANDS;

1V 209; 2 METHOXYETHOXY 8 OXO 9 (4 CARBOXY BENZYL)ADENINE; AMINE; ANTIGEN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENZOIC ACID; DEXTRAN; FICOLL; LIGAND; PEPTIDE; POLYSACCHARIDE; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 7 LIGAND; UNCLASSIFIED DRUG; VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; CELLULAR IMMUNITY; CONJUGATE; CONJUGATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INJECTION; MOLECULAR WEIGHT; MONONUCLEAR CELL; MOUSE; NEOPLASM; NONHUMAN; PHARMACODYNAMICS; ROOM TEMPERATURE; ZETA POTENTIAL; ANIMAL; BONE MARROW; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

MURINAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION; INFLAMMATION; LIGANDS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYSACCHARIDES; TOLL-LIKE RECEPTOR 7;

EID: 84939816565     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00285     Document Type: Article

References (52)

1. Akira, S., Uematsu, S., and Takeuchi, O. (2006) Pathogen recognition and innate immunity Cell 124, 783-801 10.1016/j.cell.2006.02.015
2. Akira, S. and Takeda, K. (2004) Toll-like receptor signalling Nat. Rev. Immunol. 4, 499-511 10.1038/nri1391
3. Takeda, K. and Akira, S. (2004) TLR signaling pathways Semin. Immunol. 16, 3-9 10.1016/j.smim.2003.10.003
4. Barton, G. M. and Kagan, J. C. (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization Nat. Rev. Immunol. 9, 535-42 10.1038/nri2587
5. Marrack, P., McKee, A. S., and Munks, M. W. (2009) Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9, 287-93 10.1038/nri2510
6. Steinhagen, F., Kinjo, T., Bode, C., and Klinman, D. M. (2011) TLR-based immune adjuvants Vaccine 29, 3341-55 10.1016/j.vaccine.2010.08.002
7. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002) Small anti-viral compounds activate immune cells via the TLR7MyD88-dependent signaling pathway Nat. Immunol. 3, 196-200 10.1038/ni758
8. Lee, J., Chuang, T. H., Redecke, V., She, L., Pitha, P. M., Carson, D. A., Raz, E., and Cottam, H. B. (2003) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7 Proc. Natl. Acad. Sci. U. S. A. 100, 6646-51 10.1073/pnas.0631696100
9. Kurimoto, A., Ogino, T., Ichii, S., Isobe, Y., Tobe, M., Ogita, H., Takaku, H., Sajiki, H., Hirota, K., and Kawakami, H. (2004) Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities Bioorg. Med. Chem. 12, 1091-9 10.1016/j.bmc.2003.12.008
10. Kanneganti, T. D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J. H., Franchi, L., Whitfield, J., Barchet, W., Colonna, M., and Vandenabeele, P. et al. 2006, Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3 Nature 440, 233-236 10.1038/nature04517
11. Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautes-Fridman, C., Tartour, E., Zitvogel, L., and Kroemer, G. (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy Oncoimmunology 1, 894-907 10.4161/onci.20931
12. Dockrell, D. H. and Kinghorn, G. R. (2001) Imiquimod and resiquimod as novel immunomodulators J. Antimicrob. Chemother. 48, 751-755 10.1093/jac/48.6.751
13. Meyer, T., Surber, C., French, L. E., and Stockfleth, E. (2013) Resiquimod, a topical drug for viral skin lesions and skin cancer Expert Opin. Invest. Drugs 22, 149-59 10.1517/13543784.2013.749236
14. Horscroft, N. J., Pryde, D. C., and Bright, H. (2012) Antiviral applications of Toll-like receptor agonists J. Antimicrob. Chemother. 67, 789-801 10.1093/jac/dkr588
15. Smits, E. L., Ponsaerts, P., Berneman, Z. N., and Van Tendeloo, V. F. (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Oncologist 13, 859-75 10.1634/theoncologist.2008-0097
16. Tomai, M. A., Miller, R. L., Lipson, K. E., Kieper, W. C., Zarraga, I. E., and Vasilakos, J. P. (2007) Resiquimod and other immune response modifiers as vaccine adjuvants Expert Rev. Vaccines 6, 835-47 10.1586/14760584.6.5.835
17. Chan, M., Hayashi, T., Kuy, C. S., Gray, C. S., Wu, C. C., Corr, M., Wrasidlo, W., Cottam, H. B., and Carson, D. A. (2009) Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates Bioconjugate Chem. 20, 1194-200 10.1021/bc900054q
18. Chan, M., Hayashi, T., Mathewson, R. D., Yao, S., Gray, C., Tawatao, R. I., Kalenian, K., Zhang, Y., Hayashi, Y., and Lao, F. S. et al. 2011, Synthesis and characterization of PEGylated toll like receptor 7 ligands Bioconjugate Chem. 22, 445-54 10.1021/bc1004813
19. Erstad, B. L. (1996) Viral infectivity of albumin and plasma protein fraction Pharmacotherapy 16, 996-1001
20. Chamberland, M. E., Alter, H. J., Busch, M. P., Nemo, G., and Ricketts, M. (2001) Emerging infectious disease issues in blood safety Emerging Infect. Dis. 7, 752-3 10.3201/eid0707.017731
21. Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., and Kwissa, M. et al. 2011, Programming the magnitude and persistence of antibody responses with innate immunity Nature 470, 543-U136 10.1038/nature09737
22. Goldinger, S. M., Dummer, R., Baumgaertner, P., Mihic-Probst, D., Schwarz, K., Hammann-Haenni, A., Willers, J., Geldhof, C., Prior, J. O., and Kundig, T. M. et al. 2012, Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients Eur. J. Immunol. 42, 3049-61 10.1002/eji.201142361
23. Dewitte, H., Verbeke, R., Breckpot, K., De Smedt, S. C., and Lentacker, I. (2014) Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment Nano Today 9, 743-758 10.1016/j.nantod.2014.10.001
24. Bowman, H. W. (1953) Clinical evaluation of dextran as a plasma volume expander J. Am. Med. Assoc 153, 24-26 10.1001/jama.1953.02940180026009
25. Long, D. M., Jr., Sanchez, L., Varco, R. L., and Lillehei, C. W. (1961) The use of low molecular weight dextran and serum albumin as plasma expanders in extracorporeal circulation Surgery 50, 12-28
26. Mehvar, R. (2000) Dextrans for targeted and sustained delivery of therapeutic and imaging agents J. Controlled Release 69, 1-25 10.1016/S0168-3659(00)00302-3
27. Marshall, J. D., Hessel, E. M., Gregorio, J., Abbate, C., Yee, P., Chu, M., Van Nest, G., Coffman, R. L., and Fearon, K. L. (2003) Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells Nucleic Acids Res. 31, 5122-33 10.1093/nar/gkg700
28. Khan, S., Bijker, M. S., Weterings, J. J., Tanke, H. J., Adema, G. J., van Hall, T., Drijfhout, J. W., Melief, C. J., Overkleeft, H. S., and van der Marel, G. A. et al. 2007, Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells J. Biol. Chem. 282, 21145-59 10.1074/jbc.M701705200
29. Schlosser, E., Mueller, M., Fischer, S., Basta, S., Busch, D. H., Gander, B., and Groettrup, M. (2008) TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26, 1626-37 10.1016/j.vaccine.2008.01.030
30. Zom, G. G., Khan, S., Filippov, D. V., and Ossendorp, F. (2012) TLR ligand-peptide conjugate vaccines: toward clinical application Adv. Immunol 114, 177-201
31. Bachmann, M. F. and Jennings, G. T. (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10, 787-96 10.1038/nri2868
32. Venturoli, D. and Rippe, B. (2004) Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability Am. J. Physiol Renal Physiol 288, F605-13 10.1152/ajprenal.00171.2004
33. Albanese, A., Tang, P. S., and Chan, W. C. (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 14, 1-16 10.1146/annurev-bioeng-071811-150124
34. Kulkarni, S. A. and Feng, S. S. (2013) Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery Pharm. Res. 30, 2512-22 10.1007/s11095-012-0958-3
35. Nel, A. E., Madler, L., Velegol, D., Xia, T., Hoek, E. M., Somasundaran, P., Klaessig, F., Castranova, V., and Thompson, M. (2009) Understanding biophysicochemical interactions at the nano-bio interface Nat. Mater. 8, 543-57 10.1038/nmat2442
36. Ashwell, G. (1957) Colorimetric analysis of sugars Method. Enzymol. 3, 73-105 10.1016/S0076-6879(57)03350-9
37. Thielbeer, F., Donaldson, K., and Bradley, M. (2011) Zeta potential mediated reaction monitoring on nano and microparticles Bioconjugate Chem. 22, 144-50 10.1021/bc1005015
38. Mancuso, G., Gambuzza, M., Midiri, A., Biondo, C., Papasergi, S., Akira, S., Teti, G., and Beninati, C. (2009) Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells Nat. Immunol. 10, 587-94 10.1038/ni.1733
39. Baenziger, S., Heikenwalder, M., Johansen, P., Schlaepfer, E., Hofer, U., Miller, R. C., Diemand, S., Honda, K., Kundig, T. M., and Aguzzi, A. et al. 2008, Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology Blood 113, 377-88 10.1182/blood-2008-04-151712
40. Palamara, F., Meindl, S., Holcmann, M., Luhrs, P., Stingl, G., and Sibilia, M. (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod J. Immunol. 173, 3051-61 10.4049/jimmunol.173.5.3051
41. Oh, J. Z. and Kedl, R. M. (2010) The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity J. Immunol. 185, 4602-8 10.4049/jimmunol.1001892
42. Bagnoli, F., Fontana, M. R., Soldaini, E., Mishra, R. P., Fiaschi, L., Cartocci, E., Nardi-Dei, V., Ruggiero, P., Nosari, S., and De Falco, M. G. et al. 2015, Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus Proc. Natl. Acad. Sci. U. S. A. 112, 3680-5 10.1073/pnas.1424924112
43. Underhill, D. M. and Goodridge, H. S. (2012) Information processing during phagocytosis Nat. Rev. Immunol. 12, 492-502 10.1038/nri3244
44. Wakatsuki, T., Schwab, B., Thompson, N. C., and Elson, E. L. (2001) Effects of cytochalasin D and latrunculin B on mechanical properties of cells J. Cell Sci. 114, 1025-1036
45. Danon, D., Skutelsky, E., Marikovsky, Y., and Goldstein, L. (1972) Use of Cationized Ferritin as a Label of Negative Charges on Cell Surfaces J. Ultrastruct. Res. 38, 500-510 10.1016/0022-5320(72)90087-1
46. Yeung, T., Gilbert, G. E., Shi, J., Silvius, J., Kapus, A., and Grinstein, S. (2008) Membrane phosphatidylserine regulates surface charge and protein localization Science 319, 210-3 10.1126/science.1152066
47. Dijkstra, J., Van Galen, M., and Scherphof, G. (1985) Influence of liposome charge on the association of liposomes with Kupffer cells in vitro. Effects of divalent cations and competition with latex particles Biochim. Biophys. Acta, Biomembr. 813, 287-297 10.1016/0005-2736(85)90244-5
48. Takakura, Y., Fujita, T., Hashida, M., and Sezaki, H. (1990) Disposition characteristics of macromolecules in tumor-bearing mice Pharm. Res. 7, 339-46 10.1023/A:1015807119753
49. Yamaoka, T., Kuroda, M., Tabata, Y., and Ikada, Y. (1995) Body distribution of dextran derivatives with electric charges after intravenous administration Int. J. Pharm. 113, 149-157 10.1016/0378-5173(94)00189-C
50. Foged, C., Brodin, B., Frokjaer, S., and Sundblad, A. (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 298, 315-22 10.1016/j.ijpharm.2005.03.035
51. Cho, H. J., Takabayashi, K., Cheng, P. M., Nguyen, M. D., Corr, M., Tuck, S., and Raz, E. (2000) Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism Nat. Biotechnol. 18, 509-14 10.1038/75365
52. Hayashi, T., Rao, S. P., Takabayashi, K., Van Uden, J. H., Kornbluth, R. S., Baird, S. M., Taylor, M. W., Carson, D. A., Catanzaro, A., and Raz, E. (2001) Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase Infect. Immun. 69, 6156-64 10.1128/IAI.69.10.6156-6164.2001